- Overview of Seizure-Inducing Potential of Doripenem
[作者：Zhanel, GG; Ketter, N; Rubinstein, E; Friedland, I; Redman, R,期刊：Drug safety, 页码：709-716 , 文章类型： Article，,卷期：2009年32-9]
- The seizure-inducing potential of carbapenems has been debated since the introduction of imipenem/cilastatin over 20 years ago. Doripenern is a new carbapenem, recently approved in the US for the treatment of adults with...
- Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer
[作者：Theou-Anton, N; Faivre, S; Dreyer, C; Raymond, E,期刊：Drug safety, 页码：717-734 , 文章类型： Review，,卷期：2009年32-9]
- Sunitinib is a novel, oral, multi-targeted tyrosine kinase inhibitor with antiproliferative effects against cancer cells and antiangiogenic properties. Sunitinib was recently approved for the first-line treatment of pati...
- Comparative Tolerability of Newer Agents for Insomnia
[作者：Zammit, G,期刊：Drug safety, 页码：735-748 , 文章类型： Review，,卷期：2009年32-9]
- Newer treatment options for insomnia include the non-benzodiazepine hypnotics zolpidem, zolpidem-controlled release, zaleplon, zopiclone, eszopiclone and the melatonin receptor agonist, ramelteon. These compounds are gen...
- Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates A Case Series from a Swiss University Hospital
[作者：Ing-Lorenzini, K; Desmeules, J; Plachta, O; Suva, D; Dayer, P; Peter, R,期刊：Drug safety, 页码：775-785 , 文章类型： Article，,卷期：2009年32-9]
- Background: Bisphosphonates are effective and well tolerated anti-resorptive drugs used for the treatment of osteoporosis. However, some concerns about their potential long-term negative effects are emerging. Objective: ...
- Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone Results from a 3-Year, Randomized, Comparator-Controlled Study in the US
[作者：Tolman, KG; Freston, JW; Kupfer, S; Perez, A,期刊：Drug safety, 页码：787-800 , 文章类型： Article，,卷期：2009年32-9]
- Background/aims: Non-alcoholic fatty liver disease (NAFLD), the major hepatic manifestation of type 2 diabetes mellitus, is the most common liver disease in the US. Thiazolidinediones, a commonly used drug class for the ...
|